Hester Biosciences Limited — Board Meeting, 15-05-2026: Outcome of Board Meeting

Hester Biosciences' board approved an INR 11/share dividend for FY26. Q4 consolidated net profit surged 974% to INR 16.55 Cr; full-year profit rose 99% to INR 57.48 Cr. Ms. Priya Gandhi was re-appointed ED. The company also divested a 43.81% stake in subsidiary TLPL and secured a new H9N2 vaccine license.